Halsa has acquired the exclusive intellectual property rights to ZAG, a material naturally found in humans, which induces immediate and substantial depletion of body fat as well as control of diabetic symptoms. A growing set of evidence shows that this therapeutic works in depleting body fat. Over 65% of Americans are overweight or obese, the costs of these conditions is estimated as $150 billion (half in actual health care costs), and the market for an effective prescription weight-loss therapeutic is estimated at $18 billion annually. Halsa has assembled a world-class team with exact domain expertise in pharmaceutical drug development. This project will lay the foundation for ZAG to enter full preclinical trials in preparation of an IND filing with the FDA, and subsequent clinical trials. This SBIR Phase I project will result in exploratory GLP toxicological studies in rats, a critical step in understanding possible liabilities for this promising therapeutic agent. The three specific aims of this project are: manufacture of the biologic agent, determination of its potency and toxicology studies including histopathology. , ,
Public Health Relevance: Obesity and overweight are epidemic, dangerous, expensive and largely untreated. Halsa is developing a biological drug, ZAG, a material naturally found in humans, which induces immediate and substantial depletion of body fat and also controls symptoms of diabetes. This therapeutic candidate has the potential to treat the nearly 200 million Americans afflicted with these deleterious metabolic diseases.
Thesaurus Terms: Adipocytes;Adipose Cell;Adipose Tissue;American;Animals;Anions;Biological;Body Weight Decreased;Body Fat;Cell Culture Techniques;Cell Line;Cell Lines, Strains;Cellline;Chromatography;Chromatography / Separation Science;Clinical Trials;Clinical Trials, Unspecified;Common Rat Strains;Data;Data Set;Dataset;Developed Countries;Developed Nations;Diabetes Mellitus;Dose;Drugs;Electrofocusing;Ensure;Epidemic;Fat Cells;Fatty Tissue;Foundations;Fractionation, Isoelectric Focusing;Glycoproteins;Goals;Health Care Costs;Health Costs;Healthcare Costs;Histopathology;Human;Human, General;In Vitro;Industrialized Countries;Industrialized Nations;Intellectual Property;Isoelectric Focusing;Legal Patent;Licensing;Lipid Mobilization;Lipocytes;Lipolysis;Mammalian Cell;Mammals, Rats;Mammals, Rodents;Man (Taxonomy);Man, Modern;Marketing;Materials Testing;Mature Lipocyte;Mature Fat Cell;Measures;Medication;Metabolic Diseases;Metabolic Disorder;Molecular;Obesity;Organ;Over Weight;Overweight;Patents;Pharmaceutic Preparations;Pharmaceutical Agent;Pharmaceutical Preparations;Pharmaceuticals;Pharmacologic Substance;Pharmacological Substance;Phase;Physiologic;Physiological;Preparation;Process;Programs (Pt);Programs [publication Type];Property Rights;Proteins;Protocol;Protocols Documentation;Rat;Rattus;Recombinants;Relative;Relative (Related Person);Rodent;Rodentia;Rodentias;Sbir;Sbirs (R43/44);Safety;Sampling;Small Business Innovation Research;Small Business Innovation Research Grant;Symptoms;Therapeutic;Therapeutic Agents;Thesaurismosis;Toxicokinetics;Toxicology;Transfection;Weight Loss;Weight Reduction;Work;Zinc;Zn Element;Adipose;Adiposity;Body Weight Loss;Clinical Investigation;Combat;Corpulence;Corpulency;Corpulentia;Cost;Cultured Cell Line;Design;Designing;Diabetes;Diabetic;Drug Development;Drug/Agent;Gel Electrophoresis;Gene Product;Human Subject;In Vivo;Metabolism Disorder;Novel;Obese;Obese People;Obese Person;Obese Population;Phase 1 Study;Pre-Clinical;Preclinical;Preclinical Study;Programs;Public Health Relevance;Response;Therapeutic Development;White Adipose Tissue;Wt-Loss;Yellow Adipose Tissue
